English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/179060
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1

AuthorsMarrero-Alonso, Jorge; Morales, Araceli; García Marrero, B. ; Boto, Alicia ; Marín, Raquel; Cury, Débora; Gómez, Tomás; Fernández-Pérez, Leandro; Lahoz Zamarro, Fernando; Díaz, Mario
KeywordsSelective Estrogen Receptor Modulators (SERMs)
Uterotrophic effects
Reporter-based transcriptional activity
Estrogen-dependent cell proliferation
Fluorescent derivatives
Estrogen receptor-positive breast cancer
Issue DateNov-2013
CitationEuropean Journal of Pharmaceutics and Biopharmaceutics 85(3): 898-910 (2013)
AbstractTamoxifen is a selective estrogen receptor modulator extensively used on estrogen receptor-positive breast cancer treatment. However, clinical evidences demonstrate the increased incidence of undesirable side effects during chronic therapies, the most life threatening being uterine cancers. Some of these effects are related to tissue-dependent estrogenic actions of tamoxifen, but the exact mechanisms remain poorly understood. We have designed and synthesized a novel fluorescent tamoxifen derivative, FLTX1, and characterized its biological and pharmacological activities. Using confocal microscopy, we demonstrate that FLTX1 colocalizes with estrogen receptor α (ERα). Competition studies showed that FLTX1 binding was totally displaced by unlabeled tamoxifen and partially by estradiol, indicating the existence of non-ER-related triphenylethylene-binding sites. Ligand binding assays showed that FLTX1 exhibits similar affinity for ER than tamoxifen. FLTX1 exhibited antiestrogenic activity comparable to tamoxifen in MCF7 and T47D cells transfected with 3xERE-luciferase reporter. Interestingly, FLTX1 lacked the strong agonistic effect of tamoxifen on ERα-dependent transcriptional activity. Additionally, in vivo assays in mice revealed that unlike tamoxifen, FLTX1 was devoid of estrogenic uterotrophic effects, lacked of hyperplasic and hypertrophic effects, and failed to alter basal proliferating cell nuclear antigen immunoreactivity. In the rat uterine model of estrogenicity/antiestrogenicity, FLTX1 displayed antagonistic activity comparable to tamoxifen at lower doses, and only estrogenic uterotrophy at the highest dose. We conclude that the fluorescent derivative FLTX1 is not only a suitable probe for studies on the molecular pharmacology of tamoxifen, but also a potential therapeutic substitute to tamoxifen, endowed with potent antiestrogenic properties but devoid of uterine estrogenicity.
Publisher version (URL)https://doi.org/10.1016/j.ejpb.2013.04.024
Identifiersdoi: 10.1016/j.ejpb.2013.04.024
issn: 0939-6411
e-issn: 1873-3441
Appears in Collections:(IPNA) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.